mayo clinic glp-1 oral solution drops GLP-1 Shortage = Over Have you heard of GLP-1s?

In clinical trials, participants using Zepbound achieved an average weight loss of approximately 20.2% over 72 weeks, while those on Wegovy experienced about a 13.7% reduction

Weight loss is a major secondary benefit

1-in-3 GLP-1 users say they are eating out less often as a result of being on the drugs

Youll also decrease your risk for metabolic syndrome, diabetes, and other health issues

Most GLP-1 therapies begin at a low dose and gradually increase over several weeks

Furthermore, innovations in drug delivery-such as oral formulations and once-weekly injectable options-are enhancing treatment convenience and adherence, addressing critical gaps in diabetes and obesity management